Inflammation driven by overexpression of the hypoglycosylated abnormal Mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis

Pancreas

Volumn 39, Issue 4, 2010, Pages 510-515

  Kadayakkara, Deepak K ^a   Beatty, Pamela L ^b   Turner, Michael S ^b   Janjic, Jelena M ^a   Ahrens, Eric T ^a   Finn, Olivera J ^b  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cell tracking; Inflammatory bowel disease; MRI; MUC1; Pancreatitis

Indexed keywords

FLUORINE; FLUOROCARBON; INTERLEUKIN 10; MUCIN 1; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MIGRATION; COLITIS; CONTROLLED STUDY; ENTERITIS; EPITHELIUM; GENE OVEREXPRESSION; GLYCOSYLATION; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS DUCT; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; FEMALE; GLYCOSYLATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUCIN-1; PANCREATITIS; T-LYMPHOCYTES;

EID: 77951751295     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bd6501     Document Type: Article

References (32)

1. McFarland LV. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol. 2008;14(17):2625-2629.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-434.
3. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819-4831.
4. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31(1):307-327.
5. Gurian LE, Keeffe EB. Pancreatic insufficiency associated with ulcerative colitis and pericholangitis. Gastroenterology. 1982;82(3): 581-585.
6. Herrlinger KR, Stange EF. The pancreas and inflammatory bowel diseases. Int J Pancreatol. 2000;27(3):171-179.
7. Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008; 28(5):623-628.
8. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004; 82:249-293.
9. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15(10):1087-1095.
10. Ho SB, Ewing SL, Montgomery CK, et al. Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. Oncol Res. 1996;8(2):53-61.
11. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res. 1999;59(5):1003-1007.
12. Beatty PL, Plevy SE, Sepulveda AR, et al. Cutting edge: transgenic expression of human MUC1 in IL-10j/j mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol. 2007; 179(2):735-739.
13. Longman RJ, Poulsom R, Corfield AP, et al. Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem. 2006;54(12): 1335-1348.
14. Aarnoudse CA, Garcia Vallejo JJ, Saeland E, et al. Recognition of tumor glycans by antigen-presenting cells. Curr Opin Immunol. 2006;18(1):105-111.
15. Carlos CA, Dong HF, Howard OM, et al. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol. 2005;175(3): 1628-1635.
16. Hiltbold EM, Vlad AM, Ciborowski P, et al. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol. 2000;165(7):3730-3741.
17. Monti P, Leone BE, Zerbi A, et al. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol. 2004;172(12):7341-7349.
18. Huang L, Chen D, Liu D, et al. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005;65(22):10413-10422.
19. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3-1 fibroblasts. J Biol Chem. 2004;279(20):20607-20612.
20. Schroeder JA, Adriance MC, Thompson MC, et al. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene. 2003;22(9):1324-1332.
21. Janjic JM, Srinivas M, Kadayakkara DK, et al. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc. 2008;130(9):2832-2841.
22. Ahrens ET, Flores R, Xu H, et al. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23(8):983-987.
23. Srinivas M, Morel PA, Ernst LA, et al. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med. 2007;58(4):725-734.
24. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75(2):263-274.
25. Rowse GJ, Tempero RM, VanLith ML, et al. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 1998;58(2):315-321.
26. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44(1):1-13.
27. Barthet M, Dubucquoy L, Garcia S, et al. Pancreatic changes in TNBS-induced colitis in mice. Gastroenterol Clin Biol. 2003;27(10): 895-900.
28. Barthet M, Lesavre N, Desplats S, et al. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease. Pancreatology. 2006;6(5):464-471.
29. Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis. 2004;20:73-79.
30. Vlad AM, Muller S, Cudic M, et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med. 2002;196(11):1435-1446.
31. Lagow EL, Carson DD. Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J Cell Biochem. 2002;86(4):759-772.
32. Shirasaki H, Kanaizumi E, Watanabe K, et al. Tumor necrosis factor increases MUC1 mRNA in cultured human nasal epithelial cells. Acta Otolaryngol. 2003;123(4):524-531.